Cargando…

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome

Estrogen receptor‐alpha (ERα)‐positive breast cancer is often treated with antihormonal regimens. However, resistance to treatment is common, leading to metastatic disease. ERα activity requires the functional involvement of pioneer factors FOXA1 and GATA3, which enable ERα–chromatin binding and are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schrijver, Willemijne, Schuurman, Karianne, van Rossum, Annelot, Droog, Marjolein, Jeronimo, Carmen, Salta, Sofia, Henrique, Rui, Wesseling, Jelle, Moelans, Cathy, Linn, Sabine C., van den Heuvel, Michel, van Diest, Paul, Zwart, Wilbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210032/ https://www.ncbi.nlm.nih.gov/pubmed/29972720 http://dx.doi.org/10.1002/1878-0261.12353

Ejemplares similares

Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy
por: Schrijver, Willemijne A.M.E., et al.
Publicado: (2017)

Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study
por: Schrijver, Willemijne A.M.E., et al.
Publicado: (2016)

Promoter hypermethylation profiling of distant breast cancer metastases
por: Schrijver, Willemijne A. M. E., et al.
Publicado: (2015)

Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases
por: Manson, Quirine F., et al.
Publicado: (2018)

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation
por: Severson, Tesa M., et al.
Publicado: (2016)

Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases
por: Jiwa, Laura S, et al.
Publicado: (2014)

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors
por: Singh, Abhishek A, et al.
Publicado: (2018)

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women
por: Joosten, Stacey E. P., et al.
Publicado: (2021)

Progressive APOBEC3B mRNA expression in distant breast cancer metastases
por: Sieuwerts, Anieta M., et al.
Publicado: (2017)

A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
por: Zwart, Wilbert, et al.
Publicado: (2013)

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer
por: Severson, Tesa M., et al.
Publicado: (2018)

IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer
por: Kruger, Dinja T., et al.
Publicado: (2019)

BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
por: Vos, Shoko, et al.
Publicado: (2017)

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy
por: Beelen, Karin, et al.
Publicado: (2014)

Validation of a Fully Automated HER2 Staining Kit in Breast Cancer
por: Moelans, Cathy B., et al.
Publicado: (2010)

Multiplex Ligation-Dependent Probe Amplification to Detect HER2 Amplification in Breast Cancer: New Insights in Optimal Cut-Off Value
por: Moelans, Cathy B., et al.
Publicado: (2010)

HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection
por: Moelans, Cathy B, et al.
Publicado: (2009)

Correction: ESR1 Amplification in Breast Cancer by Optimized RNase FISH: Frequent but Low-Level and Heterogeneous
por: Moelans, Cathy B., et al.
Publicado: (2014)

ESR1 Amplification in Breast Cancer by Optimized RNase FISH: Frequent but Low-Level and Heterogeneous
por: Moelans, Cathy B., et al.
Publicado: (2013)

Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer
por: Moelans, Cathy B., et al.
Publicado: (2018)

Application of Nipple Aspirate Fluid miRNA Profiles for Early Breast Cancer Detection and Management
por: Moelans, Cathy B, et al.
Publicado: (2019)

The prognostic effect of DDX3 upregulation in distant breast cancer metastases
por: Heerma van Voss, Marise R., et al.
Publicado: (2016)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Nipple Aspirate Fluid at a Glance
por: Patuleia, Susana I. S., et al.
Publicado: (2021)

PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer
por: Manson, Quirine F., et al.
Publicado: (2018)

IgA and FcαRI: Pathological Roles and Therapeutic Opportunities
por: Breedveld, Annelot, et al.
Publicado: (2019)

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot
por: Beelen, Karin, et al.
Publicado: (2018)

Low frequency of HER2 amplification and overexpression in early onset gastric cancer
por: Moelans, Cathy B., et al.
Publicado: (2011)

Foxa1 and Foxa2 Are Required for Formation of the Intervertebral Discs
por: Maier, Jennifer A., et al.
Publicado: (2013)

Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study
por: Moelans, Cathy B., et al.
Publicado: (2011)

Molecular Differences between Ductal Carcinoma In Situ and Adjacent Invasive Breast Carcinoma: A Multiplex Ligation-Dependent Probe Amplification Study
por: Moelans, Cathy B., et al.
Publicado: (2010)

The microRNA Lifecycle in Health and Cancer
por: de Rooij, Laura Adriana, et al.
Publicado: (2022)

Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer
por: Zhou, Stanley, et al.
Publicado: (2020)

The Physiological MicroRNA Landscape in Nipple Aspirate Fluid: Differences and Similarities with Breast Tissue, Breast Milk, Plasma and Serum
por: Patuleia, Susana I. S., et al.
Publicado: (2020)

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
por: Szijgyarto, Zsolt, et al.
Publicado: (2019)

Transcription factors Foxa1 and Foxa2 are required for adult dopamine neurons maintenance
por: Domanskyi, Andrii, et al.
Publicado: (2014)

Opposing Roles of FoxA1 and FoxA3 in Intrahepatic Cholangiocarcinoma Progression
por: Thanan, Raynoo, et al.
Publicado: (2020)

Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer
por: Dalm, Simone U., et al.
Publicado: (2017)

FOXA1 is a critical determinant of Estrogen Receptor function and endocrine response
por: Hurtado, Antoni, et al.
Publicado: (2010)

ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study
por: Moelans, Cathy B., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_m7kdvebfop8tugbeq53ksakq7p